Chimeric antigen receptor (CAR) T cell therapy has emerged as a novel therapeutic option for cancer patients in recent years. Despite its success, this approach faces acknowledged limitations and ...

Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity ...

A robust, ready-made and cell-based cancer therapy inches closer to reality in light of recent progress. Researchers at the MD Anderson Cancer Center released results from their Phase I/II clinical ...

Chimeric antigen receptor (CAR) T cell therapy has recently emerged as an innovative treatment option for cancer patients. Although it has been successful, this new method faces acknowledged ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target for in vivo strategies, although enhanced effector function is lost during ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Chimeric antigen receptor nature-killing cell therapy achieved “efficacy, persistence and super ...

CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using ...

A new immune cell conversion technology has been developed that directly transforms somatic cells into 'Natural Killer (NK) ...

SENTI-202, an allogeneic CAR NK cell therapy, offers a pre-manufactured option for aggressive cancers like AML, overcoming delays associated with autologous CAR T-cell therapies. The therapy's unique ...

SEOUL, South Korea, April 21, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusive ...